Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 13/20 | 0.41 |
| ▸ | BRD4 | O60885 | 12/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 2/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19152539 | 0.80 | GSK3B (0.47) | GSK3BCREBBPBRD4EP300ADORA3 | |
| SCHEMBL10309642 | 0.74 | ALDH1A1 (0.53) | CREBBPBRD4EP300ALDH1A1 | |
| SCHEMBL11914644 | 0.73 | GSK3B (0.47) | GSK3BCREBBPADORA3ADORA2AADORA1 | |
| SCHEMBL18237542 | 0.73 | GSK3B (0.34) | GSK3BADORA3ADORA2AADORA1 | |
| SCHEMBL31033318 | 0.68 | CREBBP (0.61) | GSK3BCREBBPBRD4EP300 | |
| SCHEMBL19131091 | 0.68 | CDC7 (0.47) | GSK3BTNKS2 | |
| SCHEMBL10527226 | 0.67 | TNKS (0.38) | GSK3BGSK3ACDK5CDK5R1TNKS | |
| SCHEMBL19153038 | 0.67 | GSK3B (0.56) | GSK3BCREBBPBRD4ADORA3ADORA2A | |
| SCHEMBL21061403 | 0.67 | CREBBP (0.63) | CREBBPBRD4EP300ALDH1A1 | |
| SCHEMBL10526290 | 0.67 | TNKS (0.36) | GSK3BALDH1A1GSK3ACDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO INC (US) | 2023-01-05 | — | — | US | disclosed |
| US-20190290771-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2019-09-26 | — | — | US | disclosed |
| WO-2016183359-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. (US) | 2016-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190290771-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | GSK3B 2160/4885CREBBP 4871/4885BRD4 3709/4885 |
| US-20230000993-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | GSK3B 2160/4885CREBBP 4871/4885BRD4 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.